Startups
Acionna Therapeutics
Acionna Therapeutics develops small-molecule approaches to the complement-mediated neuroimmune cascade for Alzheimer’s disease and other central nervous system disorders. Oxford Science Enterprises describes its pipeline as aiming to improve synaptic function, based on research at the University of Oxford and Cardiff University. The UK legal company Acionna Therapeutics Ltd,16309416, was incorporated March12,2025. Race Against Dementia identifies Cardiff researcher Wioleta Zelek as a co-founder and continuing scientific adviser. Five active statutory directors are registered: James Bilsland, Claire Brown, Bryan Paul Morgan, Damhnait Roisin Nicamhlaoibh and Jonathan Rex Savidge; Emma Mead’s self-published company affiliation is additionally qualified because her precise corporate role is unavailable. No clinical efficacy, trial approval or complete private employee roster is asserted. OSE publishes an active seed-stage portfolio relationship and is the registered controlling corporate shareholder from April29,2025; actual invested cash, exact financing event and paid ticket are not publicly established. Registered nominal share capital and changes in control are not funding totals or announcement dates. Alzheimer’s Research UK, the UK DRI and Race Against Dementia support antecedent academic research; those are not automatically direct company investment checks.
Founded 2025
Team
 Bryan Paul MorganDirector |
 Claire BrownDirector |
Damhnait Roisin NicamhlaoibhDirector |
Emma MeadPublic company affiliation (precise role undisclosed) |
James BilslandDirector |
Jonathan SavidgeDirector |
 Wioleta ZelekCo-Founder and Scientific Adviser |